Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to tr...Show More
peer of
competitor of
Metrics
marketSTOCKS
msh_idCOM:ZOGENIX
localeus
websitehttps://www.zogenix.com/
ipo_date2010-11-23
primary_stock_msh_idNASDAQ:ZGNX
source_refb0a9f87d-eb3a-47f1-b7ad-da19b5b89569
products_or_servicesBiopharmaceutical therapies for severe diseases